Navigation Links
Phenomix and Forest Laboratories to Collaborate on Development and Commercialization of Dutogliptin in Diabetes
Date:10/23/2008

NEW YORK and SAN DIEGO, Oct. 23, 2008 /PRNewswire-FirstCall/ -- Forest Laboratories, Inc. (NYSE: FRX) and Phenomix Corporation today announced that they have entered into a definitive collaboration agreement to develop and commercialize dutogliptin (PHX1149) in North America. Dutogliptin is Phenomix' proprietary orally administered, small molecule dipeptidyl-peptidase-4 (DPP-4) inhibitor currently undergoing Phase 3 clinical development in Type 2 diabetes mellitus.

(Logo: http://www.newscom.com/cgi-bin/prnh/20001011/FORESTLOGO )

Under the terms of the agreement, Forest will make an upfront payment to Phenomix of $75 million. Phenomix and Forest will jointly develop and commercialize dutogliptin in the United States, and the companies will equally share profits and expenses. Upon commercialization, the parties will co-promote the product in the United States, with Phenomix promoting dutogliptin to endocrinologists and diabetologists and Forest promoting to primary care and specialty physicians. Forest has exclusive rights to develop and commercialize dutogliptin in Canada and Mexico, and Phenomix will receive a royalty on sales in these countries in exchange for the rights to use jointly funded trial data in those countries. Phenomix retains development and commercialization rights to the product outside of North America, and will pay Forest a royalty on net sales in these territories. Phenomix could receive up to $340 million in upfront and milestone payments for the successful development and commercialization of dutogliptin in the United States over the term of the collaboration.

"Diabetes is a widespread and growing disease. We have
'/>"/>

SOURCE Forest Laboratories, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related biology technology :

1. Forest Laboratories, Inc. Sets Date and Conference Call for Fiscal 2009 Second Quarter Earnings
2. Oil palm plantations are no substitute for tropical rainforests, a new study shows
3. Forest Laboratories, Inc. Sets Date and Conference Call for Fiscal 2009 First Quarter Earnings
4. Forest Laboratories, Inc. and Laboratorios Almirall, S.A. to Host Webcast to Discuss Aclidinium Bromide Data Presentations at the American Thoracic Society Annual Congress
5. Forest Laboratories, Inc. and Daiichi Sankyo, Inc. Announce the Termination of the AZOR Co-Promotion Agreement
6. Forest Laboratories, Inc. Announces Amendment to Bystolic(TM) (nebivolol) Agreement
7. Forest Laboratories, Inc. Announces Positive Results of Memantine Study of Once-Daily Formulation
8. Forest Laboratories, Inc. and Merz Pharma GmbH & Co. KgaA File Additional Lawsuit Against Several Companies for Patent Infringement
9. Forest and Cypress Announce Submission of New Drug Application for Milnacipran for the Treatment of Fibromyalgia Syndrome
10. BioSpace Launches 3rd Edition of BioForest(TM) Bioscience Marketing Campaign
11. Drugs from Johnson & Johnson/Basilea and Forest Are the Most Promising Antibiotics in the Community-Acquired Pneumonia Pipeline
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2013)... 23, 2013 PuraMed BioScience ® , ... of over-the-counter (OTC) medicinal and healthcare products, announced ... the company based on low market capitalization valuation. ... All Natural Product to Treat Migraine Headaches ... Prescription Competitor , Currently Available Nationwide at ...
(Date:5/23/2013)... PI’s new LPS-24 positioners are ... mm travel range with closed-loop sensor resolution up ... these new positioners the ideal choice for high ... version is also available. , More Information: ... be found at: , http://www.physikinstrumente.com/en/products/prdetail.php?sortnr=1000745&prw-lps24 , ...
(Date:5/23/2013)... PARK, Calif. , May 23, 2013 ... oral treatment for pain has reached an important milestone, ... trial of VBY-036 - a selective cathepsin S inhibitor. ... VBY-036 is a double-blind, randomized, placebo-controlled study designed to ... doses of VBY-036 in healthy adults. "The ...
(Date:5/23/2013)... , May 23, 2013 Z Trim ... value-added ingredients to a variety of industries, announced that ... a panel discussion at this year,s National Restaurant Association ... 2013, on behalf of the Research Chefs Association.  Chef ... Restaurants: The Good, the Bad and the Ugly," joining ...
Breaking Biology Technology:PuraMed BioScience (PMBS) Issued Alert Based on Market Cap of $721,756 2PuraMed BioScience (PMBS) Issued Alert Based on Market Cap of $721,756 3Precision Positioning System Uses Miniaturezed Piezo Linear Motor: LPS-24 Linear Stage by PI 2Virobay, Inc. initiates a Phase 1 Trial of VBY-036, a compound intended for the treatment of neuropathic pain 2Virobay, Inc. initiates a Phase 1 Trial of VBY-036, a compound intended for the treatment of neuropathic pain 3Z Trim's Chef Erin Ryan sits on Expert Panel at NRA Show 2Z Trim's Chef Erin Ryan sits on Expert Panel at NRA Show 3
... of ... Directors, ... its platform technology to identify and,develop compounds that promote the growth ... announced today that it has,completed a $30 million initial closing of ...
... N.J., March 10 Palatin,Technologies, Inc. (Amex: ... Phase I,clinical trial of PL-3994, a novel, long-acting ... treatment of acute,decompensated congestive heart failure (CHF). The ... single ascending dose study,in 26 healthy volunteers who ...
... leader in,developing automated molecular testing solutions, announced today ... biotechnology companies presenting,at the 28th Annual Cowen Health ... Marriott Copley Place in Boston, Massachusetts. Fareed Kureshy,President ... of the,company, its automated molecular testing platform and ...
Cached Biology Technology:BrainCells Inc. Completes $30 Million Initial Closing of Series B Financing 2Palatin Technologies, Inc. Reports Positive Results of a Phase I Clinical Study With PL-3994 for the Treatment of Congestive Heart Failure 2Palatin Technologies, Inc. Reports Positive Results of a Phase I Clinical Study With PL-3994 for the Treatment of Congestive Heart Failure 3Palatin Technologies, Inc. Reports Positive Results of a Phase I Clinical Study With PL-3994 for the Treatment of Congestive Heart Failure 4
(Date:5/24/2013)... Orleans, LA After studying noise in one French ... not noise levels exceeded municipal ordinances, Annette Hurley, PhD, ... New Orleans, and Eric Arriaga, a third-year LSUHSC doctor ... to protect their own hearing health. Their case study ... Advance for Hearing Practice Management ., "An important part ...
(Date:5/23/2013)... , Automated conserved noncoding sequence ... evolution among grasses , Within the genome of ... that undergo little change in position and sequence over ... proteins. Some of these evolutionarily stable sequences, so-called conserved ... of other genes or the condensation of chromosomes, but ...
(Date:5/23/2013)... More than 13,000 ships per year, carrying more than 284 ... generating roughly $1.8 billion dollars in toll fees for the ... than 55 million gallons of water are used from Gatun ... 2 million people living in the isthmus. , However, ... than 20 percent of the ships at sea, has demanded ...
Breaking Biology News(10 mins):Please do try this at home 2Frontiers news briefs: May 23 2Frontiers news briefs: May 23 3Reforestation study shows trade-offs between water, carbon and timber 2Reforestation study shows trade-offs between water, carbon and timber 3
... Society for Microbiology (ASM) BD Award for Research ... Stephen Dumler, M.D., Professor, The Johns Hopkins University ... Diagnostic Systems, this award recognizes a distinguished scientist ... important applications in clinical microbiology. Dumler,s most ...
... release is available in German . ... epoch, around 115,000 years ago, there were significant climate ... from the Eemian Interglacial to the Weichselian Glacial was ... possibly at least two warming events. This is the ...
... caused more than $193 million in hospital-based medical care ... problems such as asthma and pneumonia that are triggered ... Corporation study. Researchers estimate that exposure to excessive ... emergency room visits and hospital admissions over the study ...
Cached Biology News:American Society for Microbiology honors J. Stephen Dumler 2Were short warm periods typical for transitions between interglacial and glacial epochs? 2Study finds dirty air in California causes millions worth of medical care each year 2Study finds dirty air in California causes millions worth of medical care each year 3
TNR-R2...
Complement C1q subcomponent subunit C precursor. [Source:Uniprot/SWISSPROT;Acc:P02747] Antigen: Recombinant Protein Epitope Signature Tag (PrEST)....
Sheep polyclonal to Melatonin ( Abpromise for all tested applications). Antigen: Melatonin Tg conjugate....
Goat anti-PITPN Class: Antibody Product Group: Miscellaneous Antibody...
Biology Products: